


Marinosolv® technology partnership

Solve the un(dis)solvable


Marinomed Biotech AG provides Solv4U technology partnerships to address solubility and bioavailability issues and to support formulation development of Active Pharmaceutical Ingredients (APIs) in all stages of drug discovery based on its proprietary innovative Marinosolv® technology platform.

Marinosolv® formulation



Saponins (e.g. Escin, Glycyrrhizin) and Dexpanthenol form micelles in a buffered aqueous solvent. The micelles are self-forming in aqueous solutions and have a hydrophobic core and a hydrophilic outside.

Solubilization of API




The different constituents of the Marinosolv® matrix are individually composed for an optimized formulation of each drug substance.


Marinosolv is versatile and suitable for highly hydrophobic small molecules and peptides, including APIs/NCEs at all stages of development. It is particularly useful for early stage studies that require careful consideration of each compound's unique physicochemical properties.

Marinosolv's ability to carry out solubilization studies with small drug quantities is a key benefit, making it efficient and cost-effective for drug development. This allows researchers to optimize drug delivery and test different formulations without wasting valuable compounds.

Application routes



Dosage forms



For more information, please contact our Business Development team:

E-Mail: bd@marinomed.com
Tel: +43 2262 90300



Marinomed Biotech AG
Hovengasse 25, 2100 Korneuburg, Austria

Solv4U

Solve the un(dis)solvable
www.solv4u.com